TTR
Fig. 1 · Panel C
Panel C 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Milana Bergamino Sirvén, Elena López-Knowles, Xixuan Zhu, Holly Tovey, Lucy Kilburn, Chris Holcombe, Anthony Skene, John Robertson, Judith M Bliss, Anastasia Alataki, Ian Smith, Eugene F Schuster, Mitch Dowsett, Maggie Chon U Cheang
EBioMedicine 118 105823
BACKGROUND: About 15-20% of breast cancers (BC) overexpress Human Epidermal Growth Factor Receptor 2 (HER2+), and 50% of them are also oestrogen receptor positive (ER+). Patients with ER+/HER2+ BC with a limited response to systemic therapies are at an increased risk of relapse, thus understanding the mechanisms of resistance is crucial. This study investigates the changes in gene signature expression (ΔGSE) within ER+/HER2+ tumours and their intrinsic subtype (IS) in response to peri-operative aromatase inhibitors (POAI). METHODS: We analysed paired pre-treatment (baseline) and on-treatment (2wk) samples from 313 ER+/HER2+ BC from the POETIC trial using the BC360™ codeset. Early biological response to aromatase inhibitors (AI) was assessed by immunohistochemical Ki67 levels. Association of ΔGSE with biological response was evaluated using T-test and time to recurrence (TTR) with multivariable Cox regression models adjusted for clinicopathological variables. FINDINGS: The immunity-related signatures were significantly upregulated, while proliferation, TP53 surrogate mutational status and ER-signalling were downregulated (FDR <0·05) among POAI tumours with low Ki672wk. In the POAI, 79% (59/75) of Luminal B (LumB) at baseline shifted to Luminal A (LumA) at 2wk and LumA2wk was associated with better TTR compared to LumB2wk (HR 0·2; CI 95% 0·06-0·72, p = 0·01). Based on Akaike Information Criterion scores, Ki67 and IS at 2wk provided better fit of the multivariable Cox models over the variables at baseline when predicting TTR. INTERPRETATION: Assessing on-treatment IS after POAI for ER+HER2+ BC can help to identify a group of low-risk patients with LumA2wk with good outcomes on de-escalated treatment and patients that require additional treatments. FUNDING: Cancer Research UK (CRUK/07/015).
2 个 Figure · 6 个 KM 面板
Fig. 1 Ki67 changes . Line plots of the baseline and surgery/on-treatment Ki67 levels coloured by Ki67 changes categories: High–High (H–H), High-Low (H–L), Low-High (L–H) and Low–Low (L–L) in a. POAI (n = 210) and b. control samples (n = 50). Kaplan Meier curves for TTR in POAI according to c. Ki67 2 wk High vs Low and d. Ki67 categories H–H, H-L and L–L. Cox regression analyses were all adjusted by clinicopathological variables.
Fig. 1 · Panel C
Panel C 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 1 · Panel D
Panel D 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 4 Intrinsic subtype and time to recurrence in POAI. Kaplan Meier curves for TTR according to intrinsic subtypes (4 classes) at a. baseline (n = 213), b. on-treatment timepoints (LumA as reference) (n = 213). c. Kaplan Meier curves for TTR according to LumA–LumA vs LumB-LumA (Univariable and multivariable cox regression analysis adjusted by clinicopathological variables, LumA–LumA as reference) (n = 113). d. Kaplan Meier curves for TTR according to LumB:LumA vs LumB:LumB and HER2-E:LumA vs HER2-E:HER2-E (LumB:LumA and HER2-E:LumA as reference) (n = 162). Cox regression analyses were all adjusted by clinicopathological variables.
Fig. 4 · Panel A
Panel A 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 4 · Panel B
Panel B 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 4 · Panel C
Panel C 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 4 · Panel D
Panel D 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。